PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more
PolyPeptide Group AG - Asset Resilience Ratio
PolyPeptide Group AG (PPGN) has an Asset Resilience Ratio of 9.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how PolyPeptide Group AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down PolyPeptide Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF76.69 Million | 9.92% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF76.69 Million | 9.92% |
Asset Resilience Insights
- Limited Liquidity: PolyPeptide Group AG maintains only 9.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
PolyPeptide Group AG Industry Peers by Asset Resilience Ratio
Compare PolyPeptide Group AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for PolyPeptide Group AG (2018–2024)
The table below shows the annual Asset Resilience Ratio data for PolyPeptide Group AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.02% | CHF68.28 Million | CHF756.58 Million | -4.86pp |
| 2023-12-31 | 13.89% | CHF95.71 Million | CHF689.09 Million | +7.37pp |
| 2022-12-31 | 6.52% | CHF37.53 Million | CHF575.78 Million | -16.39pp |
| 2021-12-31 | 22.91% | CHF136.30 Million | CHF595.04 Million | +18.33pp |
| 2020-12-31 | 4.58% | CHF17.21 Million | CHF375.98 Million | -1.16pp |
| 2019-12-31 | 5.74% | CHF17.51 Million | CHF305.14 Million | +2.20pp |
| 2018-12-31 | 3.54% | CHF10.04 Million | CHF283.83 Million | -- |